Company intelligence / Profile preview

EndoUVtech

Ownership: Private
Development stage: Preclinical

Overview

EndoUVtech’s proprietary UV laser and fiber optic balloon catheter has demonstrated efficacy in both animal trials at the University of Pennsylvania and human studies in Italy. The technology safely removes primary clots and dissolves smaller downstream clots that are often left behind by current mechanical devices. This dual-action approach reduces arterial damage risk by 80% compared to standard methods, with the potential to significantly improve patient recovery outcomes after stroke. The company is preparing for FDA clearance within 18–24 months.

Therapeutic areas: CardiovascularNeurology
Modalities: DeviceUV laser technologyFiber optic balloon catheter
Industry: Therapeutic Medical Devices

Partnerships

Top-tier manufacturers specializing in medical lasers and cathetersLeading global production partner for manufacturing agreement announced February 2025

Beyond the preview

Go deeper on EndoUVtech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EndoUVtech.

Explore the full profile